Midazolam is one of many bitter drugs where provision of a suitable oral paediatric formulation, particularly in the pre-anaesthetic setting, remains a challenge. To overcome this problem, a novel chocolate-based tablet formulation has been developed with positive pre-clinical results. To further investigate the potential of this formulation, 150 children aged 3-16 years who were prescribed midazolam as a premedication were randomly assigned to receive 0.5 mg.kg À1 either as the novel formulation or an intravenous solution given orally, which is the current standard at our institution. Tolerability was assessed by each child, parent and nurse using a 5-point facial hedonic scale and efficacy was determined as the time to onset of sedation. Blood samples for midazolam and 1-hydroxymidazolam levels were analysed using high-performance liquid chromatography. Population pharmacokinetics were evaluated using non-linear mixed effects modelling. The novel formulation had significantly improved tolerability scores from children, parents and nurses (all p < 0.001). Time to effect was not different between the groups (p = 0.140). The pharmacokinetics of midazolam and 1-hydroxymidazolam were able to be modelled simultaneously. The novel formulation was subject to a higher estimated first-pass metabolism compared with the intravenous solution (8.6% vs. 5.0%) and a significantly lower relative bioavailability of 82.1% (p = 0.013), with no other significant differences. Exposure relative to dose was in the range previously reported for midazolam syrup. We conclude that the novel chocolate-based formulation of midazolam provides improved tolerability while remaining efficacious with suitable pharmacokinetics when used as a premedicant for children.
Introduction
The importance of palatability for paediatric medicines, a previously neglected aspect of drug development, has recently been recognised by regulatory authorities and the pharmaceutical industry [1] [2] [3] . Midazolam, a short-acting benzodiazepine with sedative, amnesic and anxiolytic effects, is one example where the importance of this has been highlighted. Oral midazolam is commonly prescribed for children as premedication before the induction of anaesthesia. Alone, it has a bitter taste, limiting its clinical utility in the paediatric population. Only one commercially available syrup is available in some regions, so it is common practice to use the intravenous (i.v.) formulation orally. To improve tolerability, the i.v. formulation has been mixed with various palatable liquids; however, masking its taste has only been moderately successful [4, 5] .
As an alternative solution to this problem, a novel chewable chocolate-based tablet delivery system (CDS) was developed [6] . Pre-clinical data from both in-vitro and animal studies have suggested an improved acceptability of the novel formulation. Rodent data showed the CDS matrix to be effective at masking the bitter taste of midazolam. The midazolam CDS tablet did not require refrigerated storage and was stable for at least 18 months when wrapped in foil and maintained at room temperature. In-vitro drug dissolution experiments showed complete release of the midazolam load from the tablet into simulated gastric fluid in 15 min for pre-crushed tablets (to simulate mastication) and 35 min for intact tablets. Based on these data, the CDS formulation was then trialled in a paediatric population who were prescribed midazolam before general anaesthesia at our centre. We decided to assess tolerability, efficacy and safety, as well as comparative pharmacokinetics of the novel CDS formulation compared with the i.v. formulation administered orally.
Methods
We performed a prospective, open-label, single centre, Computer-generated block randomisation, stratified according to age (< 7 years old or > 7 years old) and sex, was produced by the clinical trials pharmacy in order to assign patients, and was performed independently from the During administration of the study drug, a member of the research team recorded whether the whole dose was swallowed, partially expelled or totally refused by the patient. For tolerability, the child was asked immediately after administration to record how much he or she liked the sample by putting a mark on a 5-point facial hedonic scale (ranging from 1, dislike very much; to 5, liked very much) [7] and whether they would be happy to take the drug again if required. The parent and accompanying nurse were also asked independently to give a score, using separate 5-point hedonic scales, based on their perception of how the child reacted to the taste of the assigned formulation. If the child expelled the dose immediately, the treating anaesthetist was free to decide whether a repeat dose was required, in line with current routine management. If a second dose was recommended, the treating anaesthetist, together with the parent and/or child, decided whether to repeat the dose or administer the alternative form. The time to sedation onset (clinical effect of midazolam) was recorded for all patients.
Monitoring (electrocardiography, non-invasive blood pressure measurements, capnography and pulse oximetry) was commenced and general anaesthesia was induced either by a consultant anaesthetist or under their direct supervision. The choice of anaesthetic agents and analgesia was left to the discretion of the anaesthetist. Oxygen saturation was continuously monitored throughout surgery and in the recovery area until patient discharge. One to one nursing was guaranteed at all times in the recovery area with at least one additional circulating nurse present at all times.
Given the paediatric study population undergoing otherwise usual care, a flexible, sparse venous blood sampling approach was utilised. The first sample was and coefficient of variability < 15%. The lower limit of quantification was 13 ng.ml À1 for both analytes. Therefore, all midazolam parameters were relative to bioavailability (F), whereas all 1-hydroxymidaolam parameters were relative to F x metabolic conversion (F*).
One and two additional compartments were tested for 1- Power (MCMP) method automated through Perl-speaks-NONMEM (PsN) using PK parameters from a previous study [11] to determine if the proposed sampling schedule is sufficient to determine a 20% difference between the two formulations (a clinically relevant difference). Fifty patients in each group would achieve 80% power with an a value of 0.05, whereas 75 in each group corresponded to a power of 90%. Similar results were obtained when the K a of the chocolate formulation was set 50% lower (54 and 80 in each group for a power of 80% and 90%, respectively). In order to account for dropouts and missing PK data-points, a target study population of 150 was set.
Results
One-hundred and fifty children were included in the study and baseline characteristics are shown in Table 1 group who did not entirely ingest the first dose, a decision was made by the treating anaesthetist to give a second dose, and all were given the CDS tablets. Two of the three entirely ingested the CDS tablets, whereas the other patient partially ingested this dose. Participants who did not entirely ingest the dose had a lower mean age Of these, 3% and 9%, respectively, were measurable but below the lower limit of quantification. Given these were < 10% of the total data set, they were kept at their measured values for the purposes of analysis [12] . There was an When the children with partially ingested doses were added to the analysis, the estimated dose absorbed was 70% and 58% for the CDS tablet and i.v. formulation, respectively.
The dose-normalised AUCs for both formulations were within the range which has previously been reported for midazolam syrup (Fig. 2) [11, 13] .
Discussion
This study demonstrates that the novel paediatric formulation of midazolam as a chocolate-based tablet has improved tolerability, while maintaining similar efficacy, compared with the i.v. solution given orally, the current standard at our institution. A population PK model, using sparse sampling accommodating for usual care in this paediatric population, was successfully created. This model was used to estimate the relative bioavailability between the formulations as well as to investigate differences in the absorption profiles of the two formulations.
Consistent with in-vitro and pre-clinical data [6] , we found a significant improvement in tolerability of midazolam when incorporated into the CDS tablet. Taste scores using a 5-point facial hedonic scale were significantly better for the CDS tablet when scored by children, their parents and nursing staff caring for the child. This scale has been used for taste evaluation in children from 3 to 12 years old and for parents of children aged 4-16 years [7] . Although other methods can be used, such as a visual analogue scale, this method is more commonly used, particularly in younger children. The hospital environment can be stressful for the very young and it is not surprising that they may not comply with such scoring, particularly if they dislike the taste of the premedication. Significantly, more children in the chocolate group were willing to have the same formulation again, further demonstrating an improved tolerability of this formulation.
There was no significant difference in the primary measure of efficacy between the two formulations.
Although median time to onset of sedation was 1.5 min longer in the CDS group, there was reasonable variability within each group. This difference was not statistically significant and could not be considered clinically significant either. This was so despite a 13% lower average mg.kg À1 dose for patients in the CDS group. The population PK model mirrored these findings. The estimated mean transit time for the CDS tablets was slightly longer than the i.v. formulation (13 min vs. 11 min) with significant interindividual variability (> 60% for both formulations). This difference was not significant in the PK model, with overlapping 95%CI.
Other differences between the two formulations identified in the PK model were with respect to absorption parameters. Relative bioavailability was estimated to be 82%. Considering the low reported absolute bioavailability of midazolam syrup in children (15-37%) [11, 13] Consistent with this, when a prepared mixture of the i.v.
formulation was compared with the syrup formulation, it resulted in a 45% higher serum concentration up to 90 min after administration [5] . Therefore, we would expect that the CDS tablets would have higher relative bioavailability when compared with the commercial midazolam syrup.
Developing suitable medications for children raises specific challenges, particularly with regard to ensuring tolerability and performing ethically appropriate studies in order to allow for their evaluation. The present study was designed to have minimal impact on our usual care of children while still providing key information to evaluate a new paediatric formulation. The novel CDS tablets were found to have favourable tolerability for midazolam, a drug with a bitter taste, while remaining equally efficacious, safe and with adequate relative bioavailability.
Not only does this provide a better alternative for premedication but establishes a methodology that could be applied for other bitter medications in children.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Data S1. Population pharmacokinetic modelling evaluation; method and results
